Needham & Company LLC Reiterates Buy Rating for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS - Get Free Report)'s stock had its "buy" rating reaffirmed by Needham & Company LLC in a report issued on Wednesday, Benzinga reports. They presently have a $22.00 target price on the stock. Needham & Company LLC's target price suggests a potential upside of 72.28% from the company's current price.

Several other research firms have also recently commented on EOLS. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 target price on shares of Evolus in a research note on Friday, March 1st. Barclays raised shares of Evolus from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $10.00 to $16.00 in a research note on Monday, January 29th.

Evolus Trading Down 3.9 %

Shares of EOLS stock traded down $0.52 during trading hours on Wednesday, hitting $12.77. The company's stock had a trading volume of 435,136 shares, compared to its average volume of 645,140. The business has a fifty day moving average of $13.77 and a 200-day moving average of $11.01. The stock has a market cap of $739.94 million, a price-to-earnings ratio of -11.70 and a beta of 1.45. Evolus has a twelve month low of $7.07 and a twelve month high of $15.43.

Evolus (NASDAQ:EOLS - Get Free Report) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $61.00 million for the quarter, compared to analyst estimates of $61.14 million. On average, equities analysts expect that Evolus will post -0.51 EPS for the current fiscal year.

Insider Buying and Selling at Evolus

In other Evolus news, Director Karah Herdman Parschauer sold 11,931 shares of Evolus stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $13.14, for a total value of $156,773.34. Following the transaction, the director now owns 31,243 shares in the company, valued at approximately $410,533.02. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Evolus news, insider Rui Avelar sold 27,603 shares of Evolus stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total value of $384,233.76. Following the transaction, the insider now owns 372,288 shares in the company, valued at approximately $5,182,248.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Karah Herdman Parschauer sold 11,931 shares of Evolus stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $13.14, for a total transaction of $156,773.34. Following the transaction, the director now owns 31,243 shares in the company, valued at approximately $410,533.02. The disclosure for this sale can be found here. Insiders have sold a total of 60,969 shares of company stock worth $831,005 in the last quarter. 5.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Evolus

Hedge funds and other institutional investors have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY acquired a new position in shares of Evolus during the 1st quarter valued at $26,000. Point72 Hong Kong Ltd lifted its holdings in Evolus by 979.7% in the 1st quarter. Point72 Hong Kong Ltd now owns 2,343 shares of the company's stock worth $26,000 after buying an additional 2,126 shares in the last quarter. Point72 Middle East FZE acquired a new position in Evolus in the 4th quarter worth $39,000. Tower Research Capital LLC TRC lifted its holdings in Evolus by 453.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock worth $51,000 after buying an additional 5,221 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Evolus by 353.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,614 shares of the company's stock worth $70,000 after buying an additional 5,155 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.